The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 3 February 2009, www.theannals.com, DOI 10.1345/aph.1L122.
The Annals of Pharmacotherapy: Vol. 43, No. 2, pp. 390-391. DOI 10.1345/aph.1L122
© 2009 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Junker, A.
Right arrow Articles by Farinotti, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Junker, A.
Right arrow Articles by Farinotti, R.

Stability of Oxaliplatin Solution

Audrey Junker, BS

Researcher Department of Pharmacy Pitié-Salpêtrière Hospital (Assistance Publique-Hopitaux de Paris) Paris, France

Sandrine Roy, BS

Analyst Department of Pharmacy Pitié-Salpêtrière Hospital (Assistance Publique-Hopitaux de Paris)

Marie-Catherine Desroches, PhD

Pharmacist Department of Pharmacy Pitié-Salpêtrière Hospital (Assistance Publique-Hopitaux de Paris)

Clotilde Moussay, PharmD

Pharmacist Department of Pharmacy Pitié-Salpêtrière Hospital (Assistance Publique-Hopitaux de Paris)

Malik Berhoune, PharmD

Pharmacist Department of Pharmacy Pitié-Salpêtrière Hospital (Assistance Publique-Hopitaux de Paris)

Agnès Bellanger, PharmD

Pharmacist Department of Pharmacy Pitié-Salpêtrière Hospital (Assistance Publique-Hopitaux de Paris)

Christine Fernandez, PhD

Assistant Professor and Pharmacist Department of Pharmacy Pitié-Salpêtrière Hospital (Assistance Publique-Hopitaux de Paris) 47 boulevard de l'hopital 75013 Paris, France fax 33 1-42-16-22-86 christine.fernandez{at}psl.aphp.fr

Robert Farinotti, PhD

Professor and Director Department of Pharmacy Pitié-Salpêtrière Hospital (Assistance Publique-Hopitaux de Paris)

Published Online, February 3, 2009. www.theannals.com, DOI 10.1345/aph.1L122


TO THE EDITOR: Oxaliplatin is a third-generation platinum compound for the treatment of many tumors such as colorectal cancer, refractory breast cancers, non–small-cell lung cancer, and non-Hodgkin's lymphoma. The stability of diluted solutions of oxaliplatin was not described by the manufacturer, who reported data for only 24 hours at 4 °C for the 5-mg/mL stock solution.1 More recently, Andre et al.2 have shown that 0.7-mg/mL solutions in 5% dextrose polyolefin bags were stable over 30 days at 3–7 °C and 20–24 °C. As drug stability may be influenced by concentration and interactions with plastic intravenous fluid bag material,3 we chose to study the stability of 0.25 mg/mL oxaliplatin solutions in 5% dextrose polyvinyl chloride (PVC)-free bags at 4 °C and 25 °C (protected or unprotected from light).

Methods. Nine 50-mL polyolefine Freeflex, bags containing 5% dextrose injection (Fresenius Kabi, France) were prepared from a commercial solution of oxaliplatin 5 mg/mL (Eloxatin, Aventis Pharma, UK) to obtain a diluted oxaliplatin concentration of 0.25 mg/mL. Bags were stored at 4 °C (n = 3) or at room temperature either protected (n = 3) or unprotected (n = 3) from light. The solutions were assayed immediately after preparation (day 0) and thereafter on days 1, 2, 3, 4, 7, 10, 14, 22, 28, and 90.

Oxaliplatin concentrations were determined by liquid chromatography. The system consisted of a Waters analytical instrument (Waters, France) equipped with a photodiode array detector 2996 set at 205 nm. The separation was carried out on a C18 Atlantis column (250 x 4.6 mm i.d., 5 µm). An acetonitrile–orthophosphoric acid solution (0.001 M; pH = 3.0) eluent (1:99, v/v) was used as mobile phase (1.2 mL/min). The stability of oxaliplatin was defined as not less than 90% of the initial drug concentration remaining in the solutions. The physical stability of oxaliplatin solutions was assessed by visual examination.

Results. After 90 days of storage, oxaliplatin remained stable under the 3 conditions: mean concentrations in the infusion bags were 97.8%, 96.4%, and 97.8% of the initial concentration (Figure 1). Neither precipitate nor discoloration was observed throughout the study period. Minor peaks appeared in all chromatograms and increased over the course of the study, but no major degradation was observed. Some of these impurities were already present in the commercial product before the solution was diluted. The peak area of these compounds represented 0.20% and 0.13% of the main compound on day 0 and increased up to 0.87% and 0.35% on day 90 after being stored at room temperature and not protected from light.


Figure 1
View larger version (11K):
[in this window]
[in a new window]

 
Figure 1. Evolution of oxaliplatin concentrations with time in PVC-free bags (initial concentration: 0.25 mg/mL in 5% dextrose) stored at: {square} = +4 °C; • = room temperature; {circ} = room temperature, protected from light.

 

The assay was conducted on PVC-free infusion bags, as many interactions have been described between drugs and PVC containers.3 A working concentration of 0.25 mg/mL was chosen, as it is the minimal concentration prescribed by physicians.

As described by Andre et al,2 oxaliplatin's shelf life is up to 30 days under refrigeration or at room temperature. Our results allow this stability period to be extended to 90 days in PVC-free bags at a low concentration (0.25 mg/mL). Consequently, the extended stability of 90 days allows oxaliplatin 0.25 mg/mL solutions in 5% dextrose PVC-free bags to be prepared in advance under sterile conditions in our pharmacy departments and to be stored at room temperature until their administration to patients.

References

  1. Food and Drug Administration. Eloxatin (oxaliplatin for injection). www.fda.gov/cder/foi/Label/2004/021492s004lbl.pdf (accessed 2008 Aug 8).
  2. Andre A, Cisternino S, Roy AL, et al. Stability of oxaliplatin in infusion bags containing 5% dextrose injection. Am J Health Syst Pharm 2007;64:1950-4.[Abstract/Free Full Text]
  3. Airaudo CB, Gayte-Sorbier A, Bianc C, Verdier M. Interactions between six psychotherapeutic drugs and plastic containers. Influence of plastic material and infusion solutions. Int J Clin Pharmacol Ther Toxicol 1993;31:261-6.[Medline]



This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
C. Eiden, L. Philibert, K. Bekhtari, S. Poujol, F. Malosse, and F. Pinguet
Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags
Am. J. Health Syst. Pharm., November 1, 2009; 66(21): 1929 - 1933.
[Abstract] [Full Text] [PDF]


This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Junker, A.
Right arrow Articles by Farinotti, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Junker, A.
Right arrow Articles by Farinotti, R.


homecopy help contact us subscription past issues search current issue